Key Highlights

  • Shares are trading up about 7.54% today, rebounding from Tuesday's 52-week low.
  • The FDA aligned with the company on its registrational Phase 3 trial design.
  • The trial will use a novel event-free survival primary endpoint.
  • Enrollment of about 200 adult patients is expected to begin in the second half of 2027.
  • Phase 2 data showed a 47% median reduction in total polyp burden at 12 weeks.

Recursion Pharmaceuticals (NASDAQ:RXRX) shares are trading higher today after the company announced it has aligned with the FDA on the design of its registrational Phase 3 trial for REC-4881, an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis. Recursion is a clinical-stage company pioneering AI-enabled drug discovery, using its proprietary operating system to identify drug candidates through automated biology and chemistry labs combined with machine learning.

FDA Alignment Includes a Novel Primary Endpoint

The agreed trial design uses a composite event-free survival primary endpoint that includes excision of adenomas 10 millimeters or larger throughout the gastrointestinal tract as a novel, clinically meaningful event. Adenomas of that size carry an increased risk of high-grade dysplasia and cancer, and the company said this is among the first AI-enabled programs to advance a registrational Phase 3 design for a disease with no approved pharmacologic therapies.

Phase 2 Data Showed Substantial Polyp Burden Reduction

Updated Phase 2 data presented earlier this month showed patients achieved a 47% median reduction in total polyp burden after 12 weeks of treatment, with about one in three patients achieving reductions of 65% or more. No new safety signals were observed in the update.

Trial Expected to Begin in the Second Half of 2027

The registrational trial is expected to enroll approximately 200 adult patients with the condition following colectomy or proctocolectomy and is on track to begin in the second half of 2027. Modified Spigelman stage progression and total polyp burden will be included among secondary endpoints.

Shares Rebound From a Recent 52-Week Low

Today's gain follows a stretch in which the stock touched a fresh 52-week low earlier in the week amid investor concerns over persistent losses and a cautious macro backdrop. The FDA alignment milestone offers a concrete regulatory catalyst that investors are likely to weigh against those ongoing concerns heading into the trial's planned 2027 start.